soul trial oral semaglutide cardiovascular outcomes trial: demonstrates a 14% reduction in risk of major adverse CV events soul trial oral semaglutide cardiovascular

However, from a QSR standpoint, the more important numbers might be that 18% stop use after just three months, and 31% discontinue use after six months 10

Ann Saudi Med (2012) 32:45561

Grateful! Sophia B

Many people who are at greater risk for obesity, diabetes and cardiovascular health challenges are people of color

People who successfully de-escalate may also be more motivated to tighten habits and keep up with follow-up visits, which can skew results in a small observational study

Jazmyn: I had very hard scar tissue above my C-section scar that I called my bubble and thought it could not be removed without surgery